Ann Dermatol.  2016 Feb;28(1):124-125. 10.5021/ad.2016.28.1.124.

Treatment for Refractory Pruritus Using Oral Aprepitant

• Huh JW
• Jeong YI
• Choi KH
• Park HJ
• Jue MS

• KMID: 2429499
• DOI: http://doi.org/10.5021/ad.2016.28.1.124

Abstract

No abstract available.

MeSH Terms

Pruritus*

Figure

• 

  Fig. 1 (A) Multiple excoriated papules and linear excoriations on the trunk before treatment. (B) At the 6-week follow-up, the excoriated papules and linear excoriations appear to be significantly improved.

Reference

1. Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch Dermatol Ges. 2014; 12:557–559.

2. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010; 5:e10968.

3. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012; 13:1020–1024.

4. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011; 164:665–667.

5. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010; 363:397–398.